211 related articles for article (PubMed ID: 37387559)
1. Glutamine and amino acid metabolism as a prognostic signature and therapeutic target in endometrial cancer.
Zhai L; Yang X; Cheng Y; Wang J
Cancer Med; 2023 Aug; 12(15):16337-16358. PubMed ID: 37387559
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive analysis of PHGDH for predicting prognosis and immunotherapy response in patients with endometrial carcinoma.
Zhang H; Kong W; Zhao X; Xie Y; Luo D; Chen S
BMC Med Genomics; 2023 Feb; 16(1):29. PubMed ID: 36803157
[TBL] [Abstract][Full Text] [Related]
3. Lactate metabolism-related genes to predict the clinical outcome and molecular characteristics of endometrial cancer.
Shi R; Li H; Wei S; Yu Z; Zhang J; Zhang Q; Zhou T; Yao Y; Zhang Q; Zhang T; Wang H
BMC Cancer; 2023 May; 23(1):491. PubMed ID: 37259038
[TBL] [Abstract][Full Text] [Related]
4. Identification of a metabolism-related gene expression prognostic model in endometrial carcinoma patients.
Jiang P; Sun W; Shen N; Huang X; Fu S
BMC Cancer; 2020 Sep; 20(1):864. PubMed ID: 32894095
[TBL] [Abstract][Full Text] [Related]
5. A novel five-gene metabolism-related risk signature for predicting prognosis and immune infiltration in endometrial cancer: A TCGA data mining.
Huang H; Cai X; Lin J; Wu Q; Zhang K; Lin Y; Liu B; Lin J
Comput Biol Med; 2023 Mar; 155():106632. PubMed ID: 36805217
[TBL] [Abstract][Full Text] [Related]
6. Identification of glutamine metabolism-related gene signature to predict colorectal cancer prognosis.
Xie Y; Li J; Tao Q; Wu Y; Liu Z; Zeng C; Chen Y
J Cancer; 2024; 15(10):3199-3214. PubMed ID: 38706895
[No Abstract] [Full Text] [Related]
7. Identification of a Metabolism-Related Signature for the Prediction of Survival in Endometrial Cancer Patients.
Fan Y; Li X; Tian L; Wang J
Front Oncol; 2021; 11():630905. PubMed ID: 33763366
[TBL] [Abstract][Full Text] [Related]
8. An EMT-related genes signature as a prognostic biomarker for patients with endometrial cancer.
Yu Y; Zhang Y; Li Z; Dong Y; Huang H; Yang B; Zhao E; Chen Y; Yang L; Lu J; Qiu F
BMC Cancer; 2023 Sep; 23(1):879. PubMed ID: 37723477
[TBL] [Abstract][Full Text] [Related]
9. Identification of EMT-associated LncRNA Signature for Predicting the Prognosis of Patients with Endometrial Cancer.
Shu W; Wang Z; Zhang W; Zhang J; Zhao R; Yu Z; Dong K; Wang H
Comb Chem High Throughput Screen; 2023; 26(8):1488-1502. PubMed ID: 36200154
[TBL] [Abstract][Full Text] [Related]
10. Inhibiting PHGDH with NCT-503 reroutes glucose-derived carbons into the TCA cycle, independently of its on-target effect.
Arlt B; Mastrobuoni G; Wuenschel J; Astrahantseff K; Eggert A; Kempa S; Deubzer HE
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1282-1289. PubMed ID: 34192988
[TBL] [Abstract][Full Text] [Related]
11. High Phosphoglycerate Dehydrogenase Expression Induces Stemness and Aggressiveness in Thyroid Cancer.
Jeon MJ; You MH; Han JM; Sim S; Yoo HJ; Lee WK; Kim TY; Song DE; Shong YK; Kim WG; Kim WB
Thyroid; 2020 Nov; 30(11):1625-1638. PubMed ID: 32438862
[No Abstract] [Full Text] [Related]
12. A Novel Transcription Factor-Based Prognostic Signature in Endometrial Cancer: Establishment and Validation.
Yang X; Cheng Y; Li X; Zhou J; Dong Y; Shen B; Zhao L; Wang J
Onco Targets Ther; 2021; 14():2579-2598. PubMed ID: 33880037
[TBL] [Abstract][Full Text] [Related]
13. Characterization of PHGDH expression in bladder cancer: potential targeting therapy with gemcitabine/cisplatin and the contribution of promoter DNA hypomethylation.
Yoshino H; Enokida H; Osako Y; Nohata N; Yonemori M; Sugita S; Kuroshima K; Tsuruda M; Tatarano S; Nakagawa M
Mol Oncol; 2020 Sep; 14(9):2190-2202. PubMed ID: 32386122
[TBL] [Abstract][Full Text] [Related]
14. Protein-based prognostic signature for predicting the survival and immunotherapeutic efficiency of endometrial carcinoma.
Lai J; Xu T; Yang H
BMC Cancer; 2022 Mar; 22(1):325. PubMed ID: 35337291
[TBL] [Abstract][Full Text] [Related]
15. Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase.
Dong JK; Lei HM; Liang Q; Tang YB; Zhou Y; Wang Y; Zhang S; Li WB; Tong Y; Zhuang G; Zhang L; Chen HZ; Zhu L; Shen Y
Theranostics; 2018; 8(7):1808-1823. PubMed ID: 29556358
[TBL] [Abstract][Full Text] [Related]
16. PHGDH promotes esophageal squamous cell carcinoma progression via Wnt/β-catenin pathway.
Duan X; Chen Y; Zhang K; Chen W; Zhao J; Dai X; Cao W; Dong Z; Mo S; Lu J
Cell Signal; 2023 Sep; 109():110736. PubMed ID: 37263462
[TBL] [Abstract][Full Text] [Related]
17. Reducing the serine availability complements the inhibition of the glutamine metabolism to block leukemia cell growth.
Polet F; Corbet C; Pinto A; Rubio LI; Martherus R; Bol V; Drozak X; Grégoire V; Riant O; Feron O
Oncotarget; 2016 Jan; 7(2):1765-76. PubMed ID: 26625201
[TBL] [Abstract][Full Text] [Related]
18. Significance of a PTEN Mutational Status-Associated Gene Signature in the Progression and Prognosis of Endometrial Carcinoma.
Wu Y; Wang J; Ge L; Hu Q
Oxid Med Cell Longev; 2022; 2022():5130648. PubMed ID: 35251475
[TBL] [Abstract][Full Text] [Related]
19. Construction of a microenvironment immune gene model for predicting the prognosis of endometrial cancer.
Wang Y; Zhang J; Zhou Y; Li Z; Lv D; Liu Q
BMC Cancer; 2021 Nov; 21(1):1203. PubMed ID: 34763648
[TBL] [Abstract][Full Text] [Related]
20. Identification of an immune-related risk signature and nomogram predicting the overall survival in patients with endometrial cancer.
Cheng Y; Li X; Dai Y; Dong Y; Yang X; Wang J
J Gynecol Oncol; 2021 May; 32(3):e30. PubMed ID: 33559412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
